CRISPR-TO, an engineered CRISPR-Cas13 system, delivers RNA to precise subcellular locations, enabling targeted neuronal repair. In vitro experiments on mouse neurons showed RNA delivery to neurite tips, with one RNA promoting up to 50% neurite growth within 24 hours. The technology represents a paradigm shift from DNA editing to spatially precise RNA transport, forming the foundation of 'spatial RNA medicine.' Researchers are now screening additional RNA molecules in mouse and human neurons to identify candidates for treating ALS, spinal muscular atrophy, and spinal cord injuries. The findings, published in *Nature* on May 21, 2025, highlight the potential for CRISPR-TO to revolutionize therapies for neurodegenerative diseases and injuries.
